2025 Japan Acute Kidney Injury Treatment Revenue Opportunities Report
Description
The 2025 Japan Acute Kidney Injury Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Kidney Injury Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in acute kidney injury (AKI) treatment in Japan include Asahi Kasei Medical Co. Ltd., AM-Pharma, Angion Biomedica Corp., and Fresenius Medical Care AG & Co. KGaA. Asahi Kasei Medical, a major Japanese medical device and pharmaceutical company, is significant in AKI management, driven by Japan’s aging population and rising AKI cases. AM-Pharma focuses on developing novel therapies like ilofotase alfa, targeting kidney recovery mechanisms. Angion Biomedica develops innovative treatments for AKI, while Fresenius Medical Care is a global leader in renal care, providing dialysis and renal replacement therapy crucial in AKI management.
Additionally, Japan’s healthcare system shows strong involvement of nephrologists in continuous renal replacement therapy (CRRT), a key supportive treatment for AKI, with many sessions performed in university hospitals. The Japanese Society of Nephrology promotes AKI guidelines and usage of urinary biomarkers for early detection, reflecting Japan’s proactive clinical and pharmaceutical environment. Ongoing development of innovative AKI treatments by these companies aligns with the country’s efforts to address the unmet needs in AKI beyond supportive therapies, improving patient outcomes through targeted therapeutics and renal protection strategies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Kidney Injury Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in acute kidney injury (AKI) treatment in Japan include Asahi Kasei Medical Co. Ltd., AM-Pharma, Angion Biomedica Corp., and Fresenius Medical Care AG & Co. KGaA. Asahi Kasei Medical, a major Japanese medical device and pharmaceutical company, is significant in AKI management, driven by Japan’s aging population and rising AKI cases. AM-Pharma focuses on developing novel therapies like ilofotase alfa, targeting kidney recovery mechanisms. Angion Biomedica develops innovative treatments for AKI, while Fresenius Medical Care is a global leader in renal care, providing dialysis and renal replacement therapy crucial in AKI management.
Additionally, Japan’s healthcare system shows strong involvement of nephrologists in continuous renal replacement therapy (CRRT), a key supportive treatment for AKI, with many sessions performed in university hospitals. The Japanese Society of Nephrology promotes AKI guidelines and usage of urinary biomarkers for early detection, reflecting Japan’s proactive clinical and pharmaceutical environment. Ongoing development of innovative AKI treatments by these companies aligns with the country’s efforts to address the unmet needs in AKI beyond supportive therapies, improving patient outcomes through targeted therapeutics and renal protection strategies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
